Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 15
2004 12
2005 9
2006 10
2007 24
2008 7
2009 26
2010 14
2011 20
2012 17
2013 18
2014 32
2015 24
2016 23
2017 23
2018 18
2019 30
2020 22
2021 23
2022 22
2023 23
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: boers m. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. Ann Rheum Dis. 2020. PMID: 31969328 Free article.
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M; GLORIA Trial consortium. Boers M, et al. Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31. Ann Rheum Dis. 2022. PMID: 35641125 Free PMC article. Clinical Trial.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. Smolen JS, et al. Among authors: boers m. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Free article. Review.
Reply.
Palmowski Y, Buttgereit F, Boers M. Palmowski Y, et al. Among authors: boers m. Arthritis Care Res (Hoboken). 2019 Apr;71(4):577-578. doi: 10.1002/acr.23452. Arthritis Care Res (Hoboken). 2019. PMID: 29073333 No abstract available.
A multidisciplinary lifestyle program for rheumatoid arthritis: the 'Plants for Joints' randomized controlled trial.
Walrabenstein W, Wagenaar CA, van der Leeden M, Turkstra F, Twisk JWR, Boers M, van Middendorp H, Weijs PJM, van Schaardenburg D. Walrabenstein W, et al. Among authors: boers m. Rheumatology (Oxford). 2023 Aug 1;62(8):2683-2691. doi: 10.1093/rheumatology/keac693. Rheumatology (Oxford). 2023. PMID: 36617162 Free PMC article. Clinical Trial.
Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.
D'Agostino MA, Schett G, López-Rdz A, Šenolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, Naredo E, Carron P, Duggan AM, Goyanka P, Boers M, Gaillez C. D'Agostino MA, et al. Among authors: boers m. Rheumatology (Oxford). 2022 May 5;61(5):1867-1876. doi: 10.1093/rheumatology/keab628. Rheumatology (Oxford). 2022. PMID: 34528079 Free PMC article. Clinical Trial.
Observational studies on glucocorticoids are harmful!
Boers M. Boers M. Lupus Sci Med. 2017 Apr 7;4(1):e000219. doi: 10.1136/lupus-2017-000219. eCollection 2017. Lupus Sci Med. 2017. PMID: 28409017 Free PMC article. No abstract available.
Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
D'Agostino MA, Carron P, Gaillez C, Conaghan PG, Naredo E, López-Rdz A, Šenolt L, Burgos-Vargas R, Hanova P, Padovano I, Cazenave T, Stoenoiu MS, Backhaus M, Mouterde G, Bao W, Goyanka P, Boers M, Schett G. D'Agostino MA, et al. Among authors: boers m. Semin Arthritis Rheum. 2023 Dec;63:152259. doi: 10.1016/j.semarthrit.2023.152259. Epub 2023 Aug 19. Semin Arthritis Rheum. 2023. PMID: 37660536 Free article. Clinical Trial.
379 results